Please use this identifier to cite or link to this item:
Title: Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II
Author: Vieira, Raquel
Souto, Selma B.
Sánchez-López, E. (Elena)
López-Machado, Ana
Severino, Patrícia
Jose, Sajan
Santini, Antonello
Silva, Amélia M.
Fortiuna, Ana
García López, María Luisa
Souto, Eliana B.
Keywords: Diabetis no-insulinodependent
Resistència a la insulina
Non-insulin-dependent diabetes
Insulin resistance
Issue Date: 28-Aug-2019
Publisher: MDPI
Abstract: Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
Note: Reproducció del document publicat a:
It is part of: Journal of Clinical Medicine, 2019, vol. 8, num. 9, p. 1332
Related resource:
ISSN: 2077-0383
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Files in This Item:
File Description SizeFormat 
701303.pdf653.74 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons